By admin 
The landscape of pediatric oncology research is poised for a significant advancement as CureSearch for Children’s Cancer announces the recipient of its prestigious 2026 Catapult Award. Dr. Robbie Majzner, a prominent researcher at the Dana-Farber Cancer Institute, has been awarded a $2 million investment to spearhead a Phase I clinical trial for a groundbreaking chimeric antigen receptor (CAR) T-cell therapy. This funding, provided in partnership with the Jeff Gordon Children’s Foundation, aims to address the critical unmet need for effective treatments for children and young adults suffering from relapsed or refractory neuroblastoma, a disease that remains one of the most challenging obstacles in pediatric medicine.
Neuroblastoma is a cancer that develops from immature nerve cells and is the most common extracranial solid tumor found in children. While advancements in multimodal therapy—including high-dose chemotherapy, surgical resection, radiation, and stem cell transplants—have improved outcomes for many, the prognosis for high-risk and relapsed cases remains grim. According to clinical data, neuroblastoma accounts for approximately 7% to 10% of all childhood cancers but is responsible for more than 10% of pediatric cancer deaths. For those diagnosed with high-risk disease, the five-year survival rate lingers below 50%, highlighting a desperate requirement for innovative therapeutic strategies that go beyond traditional cytotoxic treatments.
The Challenge of Solid Tumors in Immunotherapy
The emergence of CAR T-cell therapy has revolutionized the treatment of hematologic malignancies, such as acute lymphoblastic leukemia (ALL) and certain types of lymphoma. By re-engineering a patient’s own T-cells to express receptors that target specific proteins on cancer cells, scientists have achieved remarkable remission rates in blood-based cancers. However, translating this success to solid tumors like neuroblastoma has proven exceptionally difficult.
In the context of solid tumors, CAR T-cells face a hostile microenvironment. Unlike blood cancers, where malignant cells are easily accessible in the bloodstream or bone marrow, solid tumors create physical and chemical barriers that inhibit immune cell infiltration. Furthermore, once T-cells successfully enter a solid tumor, they often encounter "T-cell exhaustion." This state of dysfunction occurs when the T-cells are overstimulated by the tumor antigens, leading to a loss of effector function and a failure to persist long enough to eradicate the malignancy.
Dr. Majzner’s research specifically targets these limitations. His team’s approach focuses on GD2, a disialoganglioside highly expressed on the surface of neuroblastoma cells and other tumors of neuroectodermal origin. While GD2 has long been a target for monoclonal antibody therapies, Dr. Majzner’s next-generation CAR T-cell therapy incorporates a novel signaling architecture designed to sustain immune activity.
Technological Innovation: The ZAP70 Signaling Protein
The cornerstone of this new therapeutic approach is the integration of ZAP70, a critical signaling protein naturally found in the T-cell receptor complex. In traditional CAR T-cell designs, the signaling domains used—often derived from CD3-zeta—can lead to rapid activation but also rapid exhaustion. By redesigning the CAR architecture to include ZAP70, Dr. Majzner’s team aims to mimic the natural signaling pathways of a healthy T-cell more closely.
Preclinical studies conducted in laboratory models have shown that these redesigned CAR T-cells demonstrate superior anti-tumor activity compared to standard GD2-targeted therapies. The inclusion of ZAP70 appears to help the cells remain active for longer periods, resisting the "burnout" typically seen in solid tumor environments. Additionally, the persistence of these cells—their ability to remain in the body and provide ongoing surveillance—was significantly improved in early models, suggesting a potentially more durable response for patients.
Safety is also a paramount concern in the development of GD2-targeted therapies, as GD2 is also expressed at low levels on normal nerve fibers, which can lead to significant pain or neurological side effects during treatment. The upcoming Phase I trial will rigorously evaluate the safety profile of this next-generation therapy, determining the optimal dosage and monitoring for any adverse reactions in a clinical setting.
Bridging the "Valley of Death" in Pediatric Research
The CureSearch Catapult Award is specifically designed to address the "Valley of Death"—a metaphorical gap in drug development where promising laboratory discoveries often stall due to a lack of funding for early-stage clinical trials. While the National Institutes of Health (NIH) and other federal bodies frequently fund basic laboratory research, and pharmaceutical companies focus on late-stage trials for large markets, pediatric-specific clinical trials often struggle to find the necessary capital.
"One of the greatest challenges in pediatric cancer research is ensuring that promising discoveries reach children," said Dr. Paisley Myers, Senior Director of Research & Programs at CureSearch. "Through the Catapult Award, CureSearch helps move innovative therapies from the laboratory into clinical trials. Dr. Majzner’s work exemplifies the bold, high-potential research we were created to support."
The $2 million grant provides the essential momentum required to transition Dr. Majzner’s work from the Dana-Farber laboratories into a regulated clinical environment. This transition involves complex regulatory filings with the Food and Drug Administration (FDA), the manufacturing of clinical-grade viral vectors for cell engineering, and the intensive monitoring of the first cohort of pediatric patients.
Strategic Collaboration and Financial Support
The funding for this award is a collaborative effort between CureSearch and the Jeff Gordon Children’s Foundation. Jeff Gordon, the four-time NASCAR Cup Series champion, has long been a vocal advocate for pediatric cancer research. His foundation’s involvement underscores the importance of private philanthropy in driving medical innovation for rare and childhood diseases.
The partnership reflects a growing trend in the non-profit sector where organizations pool resources to maximize the impact of their investments. By focusing on high-risk, high-reward science, these foundations are able to support niche areas of oncology that might otherwise be overlooked by traditional commercial developers. The 2026 Catapult Award is part of a broader strategy to accelerate the timeline of drug development, ensuring that the next generation of survivors does not have to wait decades for breakthroughs.
Clinical Trial Objectives and Patient Impact
The upcoming Phase I trial will be conducted at Dana-Farber Cancer Institute, a world leader in cancer research and treatment. The primary objective of the study is to assess the safety and tolerability of the ZAP70-enhanced GD2 CAR T-cells in children and young adults with relapsed or refractory neuroblastoma. This patient population typically has few remaining options, having often exhausted standard therapies.
Secondary objectives will include measuring the persistence of the CAR T-cells in the peripheral blood and evaluating preliminary anti-tumor activity through radiographic imaging and bone marrow biopsies. Researchers will also look for biomarkers that indicate how the T-cells are interacting with the tumor microenvironment.
Dr. Majzner emphasized the urgency of this transition to clinical application. "Current GD2 CAR T cells only work in patients with small amounts of disease. We’ve designed a brand-new CAR architecture that breaks past limitations to success in lab models, and this trial will allow us to bring this advanced therapy to the children who need it most," he stated. "The CureSearch Catapult Award is vital to our mission; it gives us the momentum to catapult this science out of the lab and directly to the forefront of patient care."
Broader Implications for Oncology
The success of this trial could have implications far beyond neuroblastoma. GD2 is also expressed in other pediatric and adult malignancies, including osteosarcoma, melanoma, and certain types of brain tumors like diffuse intrinsic pontine glioma (DIPG). If the ZAP70 signaling architecture proves effective in sustaining T-cell activity against neuroblastoma, it could serve as a blueprint for engineering CAR T-cells for a wide array of solid tumors.
Furthermore, the study contributes to the broader scientific understanding of T-cell biology and synthetic immunology. By demonstrating how modified signaling pathways can overcome exhaustion, the research may inform the development of therapies for adult cancers that have similarly resisted current immunotherapy approaches.
As the 2026 trial approaches, the pediatric oncology community remains cautiously optimistic. The transition from preclinical promise to clinical reality is a rigorous process, but with the support of the Catapult Award, Dr. Majzner’s team is equipped to navigate the complexities of modern drug development. For the families of children with neuroblastoma, this research represents more than just a scientific milestone; it represents a tangible hope for a future where a diagnosis of high-risk disease is no longer a definitive sentence, but a challenge that can be overcome through the power of innovative medicine.
